From Sea to Science: Coral Aquaculture for Sustainable Anticancer Drug Development
Marine Drugs · 19.07.2024 · 22 (7) · 323
DOI: 10.3390/md22070323 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, online erschienen am 19.07.2024. Verfasst von Hung-Yu Lin und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, College of Medicine, I-Shou University, Kaohsiung 824, Taiwan. Hauptthemen laut MEDLINE: Anthozoa, Antineoplastic Agents, Biological Products, Apoptosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kaohsiung Medical University Hospital, Ministry of Science and Technology, E-Da Cancer Hospital.
Abstract (Originalsprache)
Marine natural products offer immense potential for drug development, but the limited supply of marine organisms poses a significant challenge. Establishing aquaculture presents a sustainable solution for this challenge by facilitating the mass production of active ingredients while reducing our reliance on wild populations and harm to local environments. To fully utilize aquaculture as a source of biologically active products, a cell-free system was established to target molecular components with protein-modulating activity, including topoisomerase II, HDAC, and tubulin polymerization, using extracts from aquaculture corals. Subsequent in vitro studies were performed, including MTT assays, flow cytometry, confocal microscopy, and Western blotting, along with in vivo xenograft models, to verify the efficacy of the active extracts and further elucidate their cytotoxic mechanisms. Regulatory proteins were clarified using NGS and gene modification techniques. Molecular docking and SwissADME assays were performed to evaluate the drug-likeness and pharmacokinetic and medicinal chemistry-related properties of the small molecules. The extract from Lobophytum crassum (LCE) demonstrated potent broad-spectrum activity, exhibiting significant inhibition of tubulin polymerization, and showed low IC50 values against prostate cancer cells. Flow cytometry and Western blotting assays revealed that LCE induced apoptosis, as evidenced by the increased expression of apoptotic protein-cleaved caspase-3 and the populations of early and late apoptotic cells. In the xenograft tumor experiments, LCE significantly suppressed tumor growth and reduced the tumor volume (PC3: 43.9%; Du145: 49.2%) and weight (PC3: 48.8%; Du145: 7.8%). Additionally, LCE inhibited prostate cancer cell migration, and invasion upregulated the epithelial marker E-cadherin and suppressed EMT-related proteins. Furthermore, LCE effectively attenuated TGF-β-induced EMT in PC3 and Du145 cells. Bioactivity-guided fractionation and SwissADME validation confirmed that LCE’s main component, 13-acetoxysarcocrassolide (13-AC), holds greater potential for the development of anticancer drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, College of Medicine, I-Shou University, Kaohsiung 824, Taiwan.
- Division of Urology, Department of Surgery, E-Da Cancer Hospital, I-Shou University, Kaohsiung 824, Taiwan.
- Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan.
- Graduate Institute of Marine Biology, National Dong Hwa University, Pingtung 944, Taiwan.
- Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
- Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
ORCID-Profile: Kai-Cheng Hsu, Mei-Chin Lu
Förderung
- Kaohsiung Medical University Hospital
- Ministry of Science and Technology
- E-Da Cancer Hospital
- National Health Research Institutes
- NIDDK NIH HHS
- National Dong Hwa University
Zitieren
APA
Lin, H. Y., Tsai, T. N., Hsu, K. C., Hsu, Y. M., Chiang, L. C., El-Shazly, M., Chang, K. M., Lin, Y. H., Tu, S. Y., Lin, T. E., Du, Y. C., Liu, Y. C., & Lu, M. C. (2024). From Sea to Science: Coral Aquaculture for Sustainable Anticancer Drug Development. Marine Drugs, 22(7), 323. https://doi.org/10.3390/md22070323
Vancouver
Lin HY, Tsai TN, Hsu KC, Hsu YM, Chiang LC, El-Shazly M, et al. From Sea to Science: Coral Aquaculture for Sustainable Anticancer Drug Development. Marine Drugs. 2024;22(7):323. doi:10.3390/md22070323
BibTeX
@article{Lin2024,
author = {Lin, Hung-Yu and Tsai, Tsen-Ni and Hsu, Kai-Cheng and Hsu, Yu-Ming and Chiang, Lin-Chien and El-Shazly, Mohamed and Chang, Ken-Ming and Lin, Yu-Hsuan and Tu, Shang-Yi and Lin, Tony Eight and Du, Ying-Chi and Liu, Yi-Chang and Lu, Mei-Chin},
title = {From Sea to Science: Coral Aquaculture for Sustainable Anticancer Drug Development},
journal = {Marine Drugs},
year = {2024},
volume = {22},
number = {7},
pages = {323},
doi = {10.3390/md22070323}
}
EUVIMED